Because sirtuins and NAD+ have a well-established role in cardiovascular and metabolic diseases, there is compelling experimental and clinical evidence that boosting SIRT1 activity can help treat type 2 diabetes and dyslipidemia. Here, SIRT1 is linked to metabolic syndrome.